New research reveals Alzheimer’s disease may start silently years before symptoms, offering critical insights for earlier detection and prevention strategies.
A new study suggests that Alzheimer’s disease may begin progressing biologically long before visible symptoms emerge. Scientists have identified a hidden phase of the disease that can develop much earlier than commonly assumed. The findings indicate that subtle biological changes may start well before memory loss becomes noticeable. Researchers tracked when key alterations in the brain and blood begin to accelerate across an individual’s lifespan, providing valuable clues about optimal timing for diagnosis and prevention. Experts noted that while there is currently no definitive cure, identifying when these biological processes typically begin could help guide early intervention strategies. Earlier detection may allow patients and families more time to plan care, seek support, and benefit from treatments that could slow disease progression.
CHANGES MOSTLY BEGIN IN LATE 50s
The research team analyzed data from approximately 2,100 participants. To determine when Alzheimer-related changes begin to accelerate, they evaluated blood biomarkers, brain imaging results, and cognitive performance indicators. Associate Professor Mingzhao Hu, the study’s lead author, stated that the population-based research offers a comprehensive view of age-related patterns in both biological markers and cognition. According to Hu, the results suggest that most measurable changes typically occur between the late 50s and early 70s, marking a critical period when health indicators become more pronounced.
BLOOD TESTS GAIN IMPORTANCE IN RESEARCH
Senior author Jonathan Graff-Radford emphasized that as Alzheimer research shifts toward prevention and earlier treatment, blood biomarkers will play a central role in identifying individuals most likely to benefit from interventions. Understanding when these markers begin to change and how they relate to cognitive decline can help determine the ages at which preventive screening may have the greatest impact.
The study also highlights that mapping the disease’s progression timeline could shift the focus of care from late-stage treatment to early diagnosis. Blood tests, showing patterns similar to brain imaging, are becoming increasingly important tools for tracking disease-related changes and identifying high-risk individuals. Graff-Radford noted that timing remains the most critical factor in population screening, stressing that interventions should neither begin too early nor too late, and that this research helps clarify that balance.